Clinical Trial

HJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacokinetics, and pharmacodynamics of HJB647 following single dose administration in Japanese healthy participants with elevated blood pressure and multiple dose administration with up titration in Japanese patients with hypertension, to support future clinical development of HJB647
Protocol Amendment History 3 changes
critical Recruitment opened 2026-07-23
critical Primary endpoint(s) modified 2026-07-23
notable Enrollment reduced: 74 -> 64 participants 2026-07-23
Trial Details
NCT Number NCT07644364
Lead Sponsor Novartis Pharmaceuticals
Conditions Elevated Blood Pressure, Hypertension
Enrollment 64 participants
Start Date 2026-07-02
Primary Completion 2026-12-25 (estimated)
Study Completion 2026-12-25 (estimated)
Updated on ClinicalTrials.gov 2026-07-22